Gabify Raises $175K for AI Neurodevelopmental Care

In a significant move to bolster early intervention for neurodevelopmental disorders in India, HealthTech startup Gabify has successfully closed a $175,000 pre-seed funding round. The investment was spearheaded by Inflection Point Ventures (IPV), a prominent early-stage investor known for its extensive portfolio in the Indian startup ecosystem. This capital infusion is earmarked for critical areas including clinical validation of its proprietary AI technology, further development of its platform, and strategic expansion of its core team.

Gabify is pioneering India's first comprehensive Software-as-a-Service (SaaS) ecosystem dedicated to speech and neurodevelopmental conditions. The platform leverages a sophisticated dual-AI approach, integrating voice and visual analysis to assess speech patterns, facial expressions, and behavioral cues against over 189 clinically validated criteria, aligning with established diagnostic standards like DSM-5 and CARS. This advanced methodology aims to dramatically reduce diagnostic timelines, a crucial factor in improving long-term outcomes for children.

The strategic deployment of funds will focus on refining the AI algorithms and ensuring robust clinical accuracy through a human-in-the-loop process, where expert clinicians review AI-generated insights. This commitment to validation is vital in the sensitive field of pediatric neurodevelopment. Furthermore, Gabify has also received a significant boost through the ₹25 lakhs Nidhi Seed Support Scheme award from G H Raisoni Technology Business Incubator Foundation (GHRTBI), underscoring its innovative potential and alignment with government-backed initiatives supporting high-potential startups.

Inflection Point Ventures, which has a track record of investing over INR 1200 crore across more than 280 startups, sees immense potential in Gabify's mission. Ankur Mittal, Co-founder at IPV, highlighted the critical need for early-stage intervention in neurodevelopmental challenges, stating, “Gabify is tackling this gap through a strong blend of clinical validation and AI-led innovation, enabling faster and more accurate identification of developmental conditions.” He further emphasized the platform's potential to democratize access to quality care.

Beyond the IPV investment, Gabify has garnered recognition from other influential bodies. The startup was selected among the Top 10 by DreamDeal, an initiative by Anupam Mittal, CEO of People Group and Shaadi.com, signaling its strong market potential and innovative approach. The company's technology has already undergone private beta testing in over 35 preschools and daycare centers across India, demonstrating its practical applicability and readiness for broader adoption by schools, hospitals, private practices, and non-profits.

With a clear vision to impact 1 million children by 2028 through B2B, B2C, and CSR initiatives, Gabify is set to redefine the landscape of early neurodevelopmental care. The founding team, comprising CEO Sahil Chopra with extensive startup experience, Chief Medical Officer Prachi Sood with over a decade of clinical practice at leading hospitals like Max and Fortis, and CTO Vasyl Leshchuk with deep AI and cybersecurity expertise, provides a formidable foundation for scaling this impactful venture both domestically and internationally.